BD reported Q4 revenue of $5.9 billion, up 7% reported and 3.9% organic, while full-year fiscal 2025 revenue reached a record $21.8 billion, increasing 7.7% reported and 2.9% organic. The company delivered adjusted diluted EPS of $3.96 for Q4 and a record $14.40 for the full year, representing 9.6% earnings growth despite a 2-point headwind from tariffs. Performance was driven by strong growth in BD Interventional (high single-digit organic) and Advanced Patient Monitoring (double-digit pro forma), offset by softness in Pharmaceutical Systems vaccines and Biosciences research funding. Management announced a 54th consecutive dividend increase and returned $2.2 billion to shareholders, including $1 billion in buybacks. For fiscal 2026, BD guides for low single-digit revenue growth and adjusted EPS of $14.75 to $15.05, navigating headwinds from Alaris remediation comps, China volume-based procurement, and vaccine demand, while positioning the 'New BD' as a pure-play MedTech entity post-Waters transaction.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue | $5.9 billion | +7% Reported / +3.9% Organic |
| FY25 Revenue | $21.8 billion | +7.7% Reported / +2.9% Organic |
| Q4 Adjusted EPS | $3.96 | +3.9% |
| FY25 Adjusted EPS | $14.40 | +9.6% |
| FY25 Adjusted Operating Margin | 25% | +80 bps |
| FY25 Free Cash Flow | $2.7 billion | 64% Conversion |
| FY26 Revenue Guidance | Low Single-Digit Growth | N/A |
| FY26 EPS Guidance | $14.75 - $15.05 | N/A |
| Q1 Revenue Guidance | Down Low Single Digits | N/A |
Management is aggressively accelerating the 'New BD' strategy following the FTC clearance of the Waters transaction. The company is pivoting to become a pure-play MedTech entity with over 90% consumables revenue, a profile they argue deserves a higher multiple than the current ~10x implied valuation. The spin is expected to close by the end of Q1 calendar 2026, and management projects New BD's pro forma EPS growth will be over 200 basis points higher than the WholeCo guide due to capital deployment and transaction dynamics.
BD is launching a significant commercial excellence overhaul, highlighted by the creation of a Chief Revenue Officer role filled by Mike Feld. The company is rearchitecting its operating model to align sales forces vertically with business units. They are investing an incremental $30 million in sales force expansion, specifically targeting high-growth areas like Advanced Patient Management (15% increase in sales force) and Peripheral Intervention (15% increase), as well as capitalizing on new VA reimbursement for PureWick.
The 'BD Excellence' operating model continues to drive margin expansion, enabling the company to absorb substantial tariff headwinds while still growing EPS. Management reported a record 25% adjusted operating margin for FY25, fueled by 140 basis points of gross margin expansion. They initiated a 2-year, $200 million cost-out program and reallocated $50 million from corporate costs to R&D to fund innovation in high-growth, high-margin areas like tissue regeneration and biologic drug delivery.
Capital allocation is shifting aggressively toward shareholder returns. Management announced an immediate $250 million share buyback in Q1 and committed to using at least half of the $4 billion proceeds from the Waters transaction for buybacks. This strategy is underpinned by a view that the stock is significantly undervalued, trading at roughly 10x earnings excluding the embedded Waters value, with a goal to steadily increase ROIC and free cash flow conversion.
Guidance for fiscal 2026 implies a significant slowdown to 'low single-digit' revenue growth, driven by specific, contained headwinds that management is prudently baking in. These include a >100 basis point headwind from Alaris pump comps (following a record remediation year), a mid-teens decline in China due to Volume-Based Procurement (VoBP) reaching 80% coverage, and a 25% decline in vaccine sales. While management argues these are transitory, they impact roughly 10% of the portfolio and create a tough Q1 comparison.
The Biosciences and Diagnostic Solutions (Life Sciences) segment continues to face pressure. While Diagnostic Solutions returned to positive growth, Biosciences faced 'subdued' research funding. The combined unit was roughly flat on a currency-neutral basis excluding discontinued platforms. This segment is the one being spun off to Waters, and its current sluggishness raises questions about the near-term quality of the asset being divested, though management highlights the FACSDiscover platform as a bright spot.
Tariffs remain a persistent financial drag. The company absorbed a 40 basis point headwind in FY25 and faces a significantly larger $185 million (80 basis point) headwind in FY26. While BD Excellence is generating enough productivity to offset this, the tariff situation creates a ceiling on margin expansion potential and complicates year-over-year earnings comparisons, requiring investors to look at 'ex-tariff' numbers to see true underlying performance.
Q1 specific guidance calls for revenue to be down 'low single digits' and EPS of $2.75-$2.85. This weak start is attributed to tough Biosciences comps (prior year licensing revenue) and order timing in Medical Essentials. Management warns that vaccine headwinds are disproportionately weighted to Q1, which could result in a negative stock reaction if the market focuses on the headline growth number without adjusting for these known factors.
Overall: Management conveyed a tone of confident resilience and strategic clarity. While acknowledging specific near-term macro headwinds (China, vaccines, Alaris comps) that necessitate a prudent FY26 guide, executives emphasized the strength of the core portfolio (90% of revenue) and the transformative nature of the Waters transaction. There was a noticeable shift to a more assertive, 'up-tempo' execution style regarding the 'New BD' strategy and capital allocation.
Confidence: HIGH - Management repeatedly used phrases like 'high confidence,' 'very strong track record,' and 'excited.' They provided specific, granular details on operational improvements (BD Excellence), cost savings ($200M program), and capital deployment ($250M buyback immediately), signaling strong control over the business trajectory despite external noise.
Low single-digit growth (WholeCo)
$14.75 to $15.05
~25% (consistent with FY25)
Down low single digits
$2.75 to $2.85
Down mid-teens
Decline of approximately 25%
Hedging & Uncertainty: Management frequently employed 'prudent' and 'conservative' qualifiers when discussing FY26 guidance, explicitly stating they are not assuming any macro improvement to clear the table for the 'New BD' launch. Phrases like 'transitory market dynamics' and 'contained areas' were used to downplay the impact of vaccine and China headwinds. However, regarding the long-term algorithm, hedging was minimal; they used definitive language such as 'high confidence' and 'will' regarding margin expansion and the benefits of BD Excellence, suggesting strong conviction in their operational control.
We have strong business fundamentals, high confidence in our continued long-term mid-single-digit growth profile... - Thomas Polen, Chairman, CEO and President
We're taking a prudent and transparent approach with our guidance framework. - Thomas Polen, Chairman, CEO and President
We see New BD delivering consistent mid-single-digit revenue growth over the long term... - Thomas Polen, Chairman, CEO and President
We're confident in delivering overall mid-single-digit growth over the long term as these dynamics exit... - Thomas Polen, Chairman, CEO and President
We see a clear opportunity to drive further commercial momentum. - Thomas Polen, Chairman, CEO and President
We delivered adjusted diluted EPS of $14.40, which represents strong growth of 9.6%... - Christopher DelOrefice, Executive Vice President and CFO
We're definitely going to be in the market with those cash proceeds and see this as a significant value creation opportunity. - Christopher DelOrefice, Executive Vice President and CFO
Analyst Sentiment: Analysts were focused on the conservatism of the FY26 guide, specifically questioning the low single-digit revenue start and the sustainability of margins given the top-line pressure. There was significant interest in the capital allocation strategy, specifically the rationale for the Waters spin and the aggressive buyback authorization given the stock valuation.
Management Responses: Management defended the guidance as 'prudent' and necessary to clear the table for the New BD, emphasizing that 90% of the portfolio is growing mid-single digits. They were very transparent about the specific headwinds (Alaris, China, Vaccines) causing the temporary slowdown. Regarding capital allocation, they firmly pushed back on doing more M&A, prioritizing buybacks and debt repayment to maximize shareholder value, citing a significant disconnect between intrinsic value and trading price.
Discussion on the conservatism baked into the FY26 guide regarding China, Vaccines, and Alaris comps.
Detailed explanation of the Waters transaction value accretion and the resulting 'New BD' earnings algorithm.
Clarification on the timing and impact of the $200 million cost-out program and $30 million sales force investment.
Analysis of the Alaris pump install base headwind and the transition to growth post-remediation.
Strategic rationale for aggressive share buybacks versus other uses of cash.
BD is undergoing a significant transformation into a higher-margin, pure-play MedTech company ('New BD') via the Waters spin. While the FY26 guidance appears conservative on the surface due to specific headwinds (China VoBP, Alaris comps, Vaccine softness) impacting ~10% of the portfolio, the underlying business remains robust with 90% of revenue growing mid-single digits. The BD Excellence operating system is delivering best-in-class margin expansion (25% Op Margin) and cash flow, enabling the company to absorb substantial tariff headwinds. Capital allocation is highly attractive, with management aggressively buying back stock (immediate $250M + 50% of Waters proceeds) at what they deem a deep discount to intrinsic value (trading ~10x ex-Waters). The setup offers a compelling entry point ahead of the spin-close, with the potential for EPS growth acceleration to high single-digits (ex-tariffs) and multiple re-rating as the market appreciates the quality of the New BD portfolio.
Management expects China revenue to decline mid-teens in FY26 as Volume-Based Procurement (VoBP) reaches 80% coverage of their portfolio. This creates a ~100 basis point headwind to growth.
Global vaccine demand remains soft, with management guiding for a 25% decline in vaccine sales in FY26 due to conservative ordering patterns. This impacts ~20% of the Pharm Systems business.
Positive development regarding the VA (Veterans Administration) fully reimbursing PureWick at home, creating a new growth avenue for the Interventional segment.
Tariffs remain a significant financial drag, expected to be an $185 million (80 basis point) headwind in FY26, up from 40 basis points in FY25.